非小细胞肺癌患者血浆LncRNA UCA1与吉西他滨耐药相关性研究

Study on the correlation between plasma LncRNA UCA1 and gemcitabine resistance in patients with non⁃small cell lung cancer

目的研究非小细胞肺癌患者血浆长链非编码RNA(LncRNA)上皮癌胚抗原1(UCA1)表达水平与吉西他滨耐药的相关性。方法选取2017年4月至2020年10月本院收治的非小细胞肺癌患者84例,随机分为吉西他滨组(n=43,予以吉西他滨/顺铂治疗)、紫杉醇组(n=41,予以紫杉醇/顺铂治疗),治疗结束评估疗效,并分为敏感亚组、中介亚组、耐药亚组,采用实时荧光定量PCR法测定所有患者化疗前、化疗1个周期、化疗2个周期时血浆LncRNA UCA1表达水平。结果吉西他滨组中化疗敏感19例,中介8例,耐药16例,耐药亚组化疗后LncRNA UCA1表达水平高于敏感亚组、中介亚组,差异有统计学意义(P<0.05)。化疗后吉西他滨组疾病进展(PD)患者LncRNA UCA1表达水平高于完全缓解(CR)患者、部分缓解(PR)患者、疾病稳定(SD)患者,差异有统计学意义(P<0.05)。紫杉醇组不同化疗效果患者的LncRNA UCA1表达水平比较差异无统计学意义(P>0.05)。化疗1个周期、2个周期,吉西他滨耐药亚组的LncRNA UCA1表达水平增加,敏感亚组的LncRNA UCA1表达水平下降(P<0.05),而中介亚组的LncRNA UCA1表达水平无明显变化(P>0.05)。结论非小细胞肺癌患者血浆LncRNA UCA1表达水平与吉西他滨耐药有相关性,LncRNA UCA1可作为预测吉西他滨耐药的标志物。

Objective To study the correlation between the expression level of long non⁃coding RNA(LncRNA)urothelial carcinoma associated antigen 1(UCA1)and gemcitabine resistance in lung cancer patients with non⁃small cell lung cancer(NSCLC).Methods Between April 2017 and October 2020,84 patients with NSCLC were selected and randomly divided into the gemcitabine group(43 cases treated with gemcitabine/cisplatin)and the paclitaxel group(41 cases treated with paclitaxel/cisplatin).After treatment,the curative effect was evaluated,and the patients were divided into the sensitive subgroup,the intermediate subgroup,and the drug⁃resistant subgroup.The expression levels of plasma LncRNA UCA1 in all patients before chemotherapy,after 1 cycle and 2 cycles of chemotherapy were determined by real⁃time fluorescent quantitative PCR method.Results In the gemcitabine group,19 cases were chemotherapy sensitive,8 cases were intermediary,and 16 cases were drug⁃resistant.The expression level of LncRNA UCA1 in the drug⁃resistant subgroup after chemotherapy was,higher than that in the sensitive subgroup and the intermediary subgroup(P<0.05).After chemotherapy,the expression level of LncRNA UCA1 in patients with disease progression(PD)in gemcitabine group was higher than that in patients with complete remission(CR),partial remission(PR),and stable disease(SD),and the difference was statistically significant(P<0.05).There were no significant differences in the expression level of LncRNA UCA1 between patients with different chemotherapy effects in the paclitaxel group(P>0.05). After 1 cycle and 2 cycles of chemotherapy,the expression level of LncRNA UCA1 in the gemcitabine ⁃ resistant subgroup increased,but decreased in the sensitive subgroup(P< 0.05). There is no significant change in the intermediate subgroup(P>0.05). Conclusion The expression level of plasma LncRNA UCA1 in patients with NSCLC is correlated with gemcitabine resistance. LncRNA UCA1 can be used as a marker to predict gemcitabine resistance.